Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Targeting of Indoleamine 2,3 Dioxygenase ‐Mediated Immune Escape in Cancer

10 Sept 2014

Abstract excerpt

The era of immunotherapies was unleashed in 2010 with the Food and Drug Administration (FDA) approval of the first therapeutic vaccine sipuleucel-T as a standard treatment for metastatic prostate cancer. Next, the first immune-activating anticytotoxic lymphocyte antigen-4 (CTLA-4) antibody ipilimumab exhibiting 'immune checkpoint blockade' was approved by FDA and European Medical Agency (EMA) for the treatment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cancer, Stress, Anesthesia, and Immune Response
Share to Tryptophan and brain disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25207460
DOI: 10.1111/bcpt.12320

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Targeting of Indoleamine 2,3 Dioxygenase ‐Mediated Immune Escape in CancerPMID 25207460Read ↗

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the pastSemantic proximity Read ↗

Natural CD4+ T-Cell Responses against Indoleamine 2,3-DioxygenaseSemantic proximity Read ↗

Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumabSemantic proximity Read ↗

Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanomaSemantic proximity Read ↗

Current Challenges for IDO2 as Target in Cancer ImmunotherapySemantic proximity Read ↗

The indoleamine 2,3 dioxygenase pathway drives intratumoral B cell maintenanceSemantic proximity Read ↗

Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanomaSemantic proximity Read ↗

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?Semantic proximity Read ↗

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responsesSemantic proximity Read ↗

Restructuring of the Immune Contexture Improves Checkpoint Blockade Efficacy in Murine Lung CancerSemantic proximity Read ↗

Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cellsSemantic proximity Read ↗

Indoleamine 2,3-Dioxygenase and Dendritic Cell TolerogenicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.